- BeiGene's (NASDAQ:BGNE) BLINCYTO (blinatumomab) for injection for the treatment of adult patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL) has been approved in China.
- The BLA had been submitted by Amgen (NASDAQ:AMGN) and has received priority review in the region.
- Developed by Amgen and licensed to BeiGene in China under a strategic collaboration commenced earlier this year, this is the first approval for BLINCYTO in China and BeiGene’s first product licensed from Amgen to be newly approved.
- https://seekingalpha.com/news/3642375-beigenes-blincyto-okd-in-china-for-blood-and-bone-marrow-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.